Stryker Co. (NYSE:SYK) Director Srikant M. Datar sold 350 shares of the company’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $215.00, for a total transaction of $75,250.00. Following the sale, the director now owns 6,844 shares of the company’s stock, valued at approximately $1,471,460. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Shares of SYK stock traded up $1.70 on Friday, hitting $217.00. The stock had a trading volume of 1,226,400 shares, compared to its average volume of 1,090,037. Stryker Co. has a twelve month low of $144.75 and a twelve month high of $222.59. The firm has a market cap of $79.33 billion, a P/E ratio of 27.43, a PEG ratio of 2.57 and a beta of 0.85. The company has a current ratio of 2.07, a quick ratio of 1.26 and a debt-to-equity ratio of 0.67. The company has a fifty day moving average price of $210.77 and a two-hundred day moving average price of $194.99.
Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 25th. The medical technology company reported $1.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.93 by $0.05. Stryker had a net margin of 24.99% and a return on equity of 25.98%. The company had revenue of $3.65 billion during the quarter, compared to analyst estimates of $3.60 billion. During the same quarter in the previous year, the business earned $1.76 EPS. The firm’s revenue was up 9.9% on a year-over-year basis. On average, analysts expect that Stryker Co. will post 8.2 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 0.96%. The ex-dividend date is Friday, September 27th. Stryker’s dividend payout ratio (DPR) is 28.45%.
Several analysts have commented on SYK shares. ValuEngine upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Raymond James set a $240.00 target price on shares of Stryker and gave the company a “buy” rating in a research report on Friday, July 26th. Zacks Investment Research upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $225.00 target price for the company in a research report on Monday, July 29th. Morgan Stanley upped their target price on shares of Stryker from $218.00 to $230.00 and gave the company an “overweight” rating in a research report on Tuesday, July 16th. Finally, Piper Jaffray Companies upped their target price on shares of Stryker from $205.00 to $240.00 and gave the company an “overweight” rating in a research report on Friday, July 26th. Five analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. Stryker has an average rating of “Buy” and an average target price of $214.89.
Several hedge funds have recently made changes to their positions in SYK. Nuveen Asset Management LLC grew its holdings in shares of Stryker by 20,218.6% in the 2nd quarter. Nuveen Asset Management LLC now owns 2,596,110 shares of the medical technology company’s stock valued at $533,708,000 after buying an additional 2,583,333 shares during the period. FMR LLC grew its holdings in shares of Stryker by 13.4% in the 1st quarter. FMR LLC now owns 6,728,182 shares of the medical technology company’s stock valued at $1,328,951,000 after buying an additional 793,560 shares during the period. Vanguard Group Inc. grew its holdings in shares of Stryker by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 26,735,288 shares of the medical technology company’s stock valued at $5,496,241,000 after buying an additional 555,327 shares during the period. Ellis Investment Partners LLC grew its holdings in shares of Stryker by 19,658.9% in the 1st quarter. Ellis Investment Partners LLC now owns 367,318 shares of the medical technology company’s stock valued at $367,000 after buying an additional 365,459 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Stryker by 6.5% in the 4th quarter. Geode Capital Management LLC now owns 3,665,205 shares of the medical technology company’s stock valued at $573,387,000 after buying an additional 224,785 shares during the period. 73.48% of the stock is owned by institutional investors.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Recommended Story: What is a stock buyback?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.